Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 5,280 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,280 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $51.66, for a total value of $272,764.80. Following the completion of the sale, the chief executive officer owned 90,920 shares in the company, valued at $4,696,927.20. This trade represents a 5.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.68, for a total value of $556,300.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total value of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total value of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total value of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total value of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total value of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total transaction of $3,005,705.34.

Phibro Animal Health Stock Up 0.3%

Shares of Phibro Animal Health stock traded up $0.15 during trading on Thursday, reaching $52.38. 347,486 shares of the company traded hands, compared to its average volume of 255,491. The firm has a market capitalization of $2.12 billion, a PE ratio of 23.28, a P/E/G ratio of 0.80 and a beta of 0.74. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $56.30. The company has a 50 day moving average price of $47.34 and a 200-day moving average price of $42.65. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, equities research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be issued a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 0.9%. Phibro Animal Health’s dividend payout ratio is presently 21.33%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PAHC. Penserra Capital Management LLC bought a new position in Phibro Animal Health during the 3rd quarter valued at $519,000. Capricorn Fund Managers Ltd bought a new stake in shares of Phibro Animal Health in the 3rd quarter worth $10,233,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Phibro Animal Health in the third quarter valued at about $8,931,000. Citigroup Inc. raised its holdings in shares of Phibro Animal Health by 112.3% in the third quarter. Citigroup Inc. now owns 54,941 shares of the company’s stock valued at $2,223,000 after purchasing an additional 29,066 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Phibro Animal Health during the second quarter valued at about $813,000. Institutional investors own 99.34% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research note on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Phibro Animal Health has an average rating of “Moderate Buy” and a consensus price target of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.